Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies

Patients with hematological malignancies have impaired immune response after two doses of BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2. Here, in this observational study (registration number HDH F20210324145532), we measure SARS-CoV-2 anti-Spike antibodies, neutralizing antibodies and T-cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Re, Daniel, Seitz-Polski, Barbara, Brglez, Vesna, Carles, Michel, Graça, Daisy, Benzaken, Sylvia, Liguori, Stéphane, Zahreddine, Khaled, Delforge, Margaux, Bailly-Maitre, Béatrice, Verrière, Benjamin, Chamorey, Emmanuel, Barrière, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844396/
https://www.ncbi.nlm.nih.gov/pubmed/35165284
http://dx.doi.org/10.1038/s41467-022-28578-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844396/
https://www.ncbi.nlm.nih.gov/pubmed/35165284
http://dx.doi.org/10.1038/s41467-022-28578-0

Ejemplares similares